LoadingLoadingLoadingNet selling: insiders sold $24.9M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsEach bar is 100% of that source’s money. The notch marks an even split.
Lean is the direction of the latest moves. Descriptive, not advice.
Buys/Adds (1)
Two Sigma
$92.7M
added
Sells/Trims (2)
Point72
$67.8M
sold
D.E. Shaw
$35.4M
trimmed
No tracked top-trader positions in JAZZ as of Oct 21, 18:07 UTC.
Hyperliquid positioning - not every stock is covered
Last report
Aug 3, 2026
Period ending
Jun 30, 2026
Earnings per share
$6.18 expected
Revenue
Financial statements: Alpha Vantage
Estimates as of Oct 21, 2026
EPS expected
-$4.93 to $6.95
Revenue expected
18 analysts
Last 30 days
Analysts raising estimates
Estimate drift
Change in 30 days
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / income | Surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 3, 2026 | $5.71 / $6.18Yahoo Finance | -7.54% miss | $1.21B No estimate | Unavailable |
| Mar 31, 2026 | May 5, 2026 | $6.34 / $4.66Yahoo Finance | +36.18% beat | $1.07B No estimate | Unavailable |
| Dec 31, 2025 | Feb 24, 2026 | $6.64 / $6.51Yahoo Finance | +2.05% beat | $1.20B No estimate | Unavailable |
| Sep 30, 2025 | Nov 5, 2025 | $8.13 / $5.85Yahoo Finance | +38.97% beat | $1.13B No estimate | Unavailable |
| Jun 30, 2025 | Aug 5, 2025 | -$8.25 / -$6.25Alpha Vantage | -32.00% miss | $1.05B No estimate | Unavailable |
| Mar 31, 2025 | May 6, 2025 | $1.68 / $4.66Alpha Vantage | -63.95% miss | $897.8M No estimate | Unavailable |
| Dec 31, 2024 | Feb 25, 2025 | $6.60 / $5.81Alpha Vantage | +13.58% beat | $1.09B No estimate | Unavailable |
| Sep 30, 2024 | Nov 6, 2024 | $6.61 / $5.50Alpha Vantage | +20.18% beat | $1.05B No estimate | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue and income use company releases, SEC filings, Alpha Vantage or Yahoo Finance. Non-USD revenue carries its currency code. Comparisons require a paired release estimate.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $1.13B | $1.20B | $1.07B | $1.21B |
| Cost of what it sold | $257.8M | $24.6M | $306.4M | $116.4M |
| Gross profit | $868.3M | $1.17B | $762.5M | $1.09B |
| What it spent | ||||
| Research and development | $240.7M | $171.4M | $134.1M | $207.5M |
| Sales and admin | $530.6M | $406.2M | $352.7M | $389.2M |
| Other operating costs | $39.5M | -$313.5M | $61.9M | $247.0M |
| Total operating expenses | $810.8M | $264.1M | $548.7M | $843.7M |
| What was left | ||||
| Operating profit | $57.5M | $909.2M | $213.8M | $248.2M |
| Interest on debt | $48.6M | $45.4M | $63.3M | $37.1M |
| Profit before tax | $9.0M | $208.3M | $299.2M | $211.0M |
| Tax | -$242.4M | $4.9M | $6.1M | $18.1M |
| Net profit | $251.4M | $203.5M | $293.1M | $192.8M |
| EBITDA | $235.9M | $432.9M | $543.9M | $427.2M |
This stock is under pressure.
Trend
Under pressure
0 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage leans bullish
Jazz Pharmaceuticals stock trades at EUR 185.18 ahead of November 2 results
NeutralOct 20Jazz Pharmaceuticals stock trades at EUR 185.18 ahead of November 2 results
NeutralOct 20Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 2, 2026
NeutralOct 19Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 2, 2026
NeutralOct 19Jazz Pharmaceuticals plc (JAZZ) Stock forecasts
Leans bearishOct 18Citi keeps USD 325 target for Jazz Pharmaceuticals stock
Leans bullishOct 18Why Everyone Is Watching Jazz Pharmaceuticals (JAZZ) Right Now
NeutralOct 18Why Everyone Is Watching Jazz Pharmaceuticals (JAZZ) Right Now
NeutralOct 18
